PGClα-MEDIATED MITOFUSIN-2 DEFICIENCY IN PULMONARY ARTERIAL HYPERTENSION CAN BE REGRESSED BY PRO-FUSION AND ANTI-FISSION THERAPY
John Ryan(Northwestern University), Stephen L. Archer(Queen's University), Erik Morrow(University of Alberta), Hannah Zhang(St. Boniface Hospital), Péter T. Tóth(University of Chicago), Chad R. Haney(Northwestern University), Nancy Luo(University of Chicago), Glenn Marsboom(Johnson & Johnson (United States)), Chin-Tu Chen(University of Chicago), Yong Hu Fang(University of Chicago), Willard W. Sharp(University of Chicago), Zhigang Hong(University of Chicago), Kyle Ericson(University of Chicago)
Cited by 0
Related Papers
Pediatric Pulmonary Hypertension
|Circulation|2015|1.1k
Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer
|The FASEB Journal|2012|606
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
|Nature Medicine|2021|599
Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension
|Circulation|2002|578
Basic Science of Pulmonary Arterial Hypertension for Clinicians
|Circulation|2010|488